Refsum Disease
Overview
Plain-Language Overview
Refsum Disease is a rare inherited disorder that affects the body's ability to break down a fatty acid called phytanic acid. This condition primarily impacts the nervous system, leading to problems with movement, sensation, and vision. People with this disease often experience night blindness, difficulty walking, and a loss of feeling in the hands and feet. It can also cause an unusual smell on the skin and heart problems. The disease results from a buildup of phytanic acid in the blood and tissues, which damages nerves and other organs. Early symptoms usually appear in childhood or adolescence and worsen over time. Managing the disease involves controlling the levels of phytanic acid to reduce symptoms.
Clinical Definition
Refsum Disease is an autosomal recessive peroxisomal disorder characterized by the accumulation of phytanic acid due to defective alpha-oxidation. The most common cause is mutations in the PHYH gene encoding phytanoyl-CoA hydroxylase, or less commonly in the PEX7 gene affecting peroxisomal biogenesis. This leads to toxic accumulation of phytanic acid in plasma and tissues, causing progressive neurological dysfunction including retinitis pigmentosa, peripheral neuropathy, cerebellar ataxia, and hearing loss. Additional features include anosmia, ichthyosis, and cardiac arrhythmias. The disease is clinically significant due to its progressive nature and potential for severe disability if untreated. Diagnosis relies on biochemical detection of elevated phytanic acid and genetic testing. Early recognition is critical to prevent irreversible neurological damage.
Inciting Event
Initial exposure to dietary phytanic acid triggers symptom onset in genetically predisposed individuals.
Lack of early dietary restriction allows phytanic acid accumulation to reach toxic levels.
Progressive enzyme deficiency leads to gradual symptom development without a single acute trigger.
Latency Period
Symptoms typically develop over years to decades after birth due to gradual phytanic acid accumulation.
Clinical manifestations often appear in late childhood to early adulthood despite lifelong enzyme deficiency.
Delay between dietary exposure and symptom onset can be variable depending on phytanic acid intake.
Diagnostic Delay
Early symptoms such as retinitis pigmentosa and neuropathy are nonspecific and often misdiagnosed.
Lack of awareness about rare peroxisomal disorders leads to delayed biochemical testing.
Overlap with other neurologic and ophthalmologic diseases causes misattribution of symptoms.
Limited access to specialized metabolic testing for phytanic acid levels delays diagnosis.
Clinical Presentation
Signs & Symptoms
Night blindness and progressive peripheral vision loss from retinitis pigmentosa
Peripheral neuropathy causing numbness, paresthesias, and weakness
Cerebellar ataxia with unsteady gait and coordination difficulties
Ichthyosis with dry, scaly skin patches
Hearing loss due to sensorineural involvement
Anosmia or loss of smell in some patients
History of Present Illness
Progressive night blindness and visual field constriction due to retinitis pigmentosa.
Gradual onset of peripheral neuropathy with numbness, paresthesias, and muscle weakness.
Development of ataxia and cerebellar signs including gait instability and dysarthria.
Presence of ichthyosis and anosmia in some patients.
Cardiac conduction abnormalities and heart failure symptoms may appear in advanced disease.
Past Medical History
History of early-onset retinitis pigmentosa or unexplained peripheral neuropathy.
Previous episodes of ataxia or muscle weakness without clear etiology.
No prior significant exposures except for dietary intake of phytanic acid-rich foods.
Absence of other peroxisomal or metabolic disorders unless part of a broader syndrome.
Family History
Presence of affected siblings or relatives with similar neurologic or visual symptoms.
Consanguineous parents increase likelihood of autosomal recessive inheritance.
Family history may reveal undiagnosed cases of retinitis pigmentosa or neuropathy.
Genetic testing may identify biallelic mutations in PHYH or PEX7 in affected family members.
Physical Exam Findings
Retinitis pigmentosa with characteristic bone-spicule pigmentation on fundoscopic exam
Peripheral neuropathy manifesting as decreased sensation and diminished deep tendon reflexes
Cerebellar ataxia evidenced by gait instability and dysmetria
Ichthyosis presenting as dry, scaly skin
Shortened metacarpals or metatarsals sometimes observed on skeletal exam
Diagnostic Workup
Diagnostic Criteria
Diagnosis is established by demonstrating elevated plasma phytanic acid levels above the normal reference range. Clinical features such as retinitis pigmentosa, peripheral neuropathy, and cerebellar ataxia support the diagnosis. Confirmatory testing includes genetic analysis identifying pathogenic variants in the PHYH or PEX7 genes. Additional supportive findings include abnormal nerve conduction studies and characteristic ophthalmologic changes. Biochemical assays of peroxisomal function may also aid diagnosis.
Pathophysiology
Key Mechanisms
Deficiency of phytanoyl-CoA hydroxylase enzyme due to mutations in the PHYH gene leads to impaired alpha-oxidation of phytanic acid.
Accumulation of phytanic acid in plasma and tissues causes toxic lipid storage affecting multiple organ systems.
Disruption of myelin sheath integrity and neuronal function results in progressive neurologic symptoms.
Phytanic acid accumulation induces retinal degeneration causing visual impairment.
Peripheral nerve demyelination leads to sensorimotor neuropathy and muscle weakness.
| Involvement | Details |
|---|---|
| Organs | Liver is the site of defective peroxisomal alpha-oxidation causing phytanic acid buildup in Refsum disease. |
Eyes are affected by retinal degeneration leading to progressive vision loss and night blindness. | |
Peripheral nervous system involvement leads to sensory ataxia and polyneuropathy characteristic of the disease. | |
| Tissues | Peripheral nerves are affected by demyelination and axonal degeneration due to phytanic acid toxicity, causing neuropathy. |
Retinal tissue undergoes degeneration resulting in retinitis pigmentosa, a hallmark ocular feature of the disease. | |
| Cells | Hepatocytes are involved in the defective alpha-oxidation of phytanic acid leading to its accumulation in Refsum disease. |
Neurons are damaged by phytanic acid accumulation causing progressive neurological symptoms. | |
| Chemical Mediators | Phytanic acid accumulation is the primary toxic metabolite responsible for the clinical manifestations of Refsum disease. |
Peroxisomal enzymes involved in alpha-oxidation are deficient or dysfunctional, leading to impaired phytanic acid metabolism. |
Treatments
Pharmacological Treatments
Non-pharmacological Treatments
A strict dietary restriction of phytanic acid intake by avoiding foods like dairy products, ruminant fats, and certain fish is the cornerstone of treatment.
Plasmapheresis or lipid apheresis can be used to rapidly reduce elevated phytanic acid levels in severe or acute cases.
Supportive therapies including physical therapy and ophthalmologic care help manage neurological and retinal complications.
Prevention
Pharmacological Prevention
Dietary restriction of phytanic acid intake to prevent accumulation
Plasmapheresis to reduce circulating phytanic acid levels in severe cases
Vitamin E supplementation as an antioxidant adjunct therapy
Management of cardiac arrhythmias with antiarrhythmic drugs when indicated
Use of neuropathic pain agents to control symptoms
Non-pharmacological Prevention
Avoidance of phytanic acid-rich foods such as dairy, ruminant fats, and certain fish
Regular ophthalmologic screening to monitor retinal degeneration
Physical therapy to maintain mobility and reduce fall risk
Genetic counseling for affected families
Skin care regimens to manage ichthyosis and prevent infections
Outcome & Complications
Complications
Progressive vision loss leading to blindness
Severe peripheral neuropathy causing disability and falls
Cardiac conduction defects potentially resulting in sudden death
Chronic skin infections due to ichthyosis
Respiratory complications from neuromuscular weakness
| Short-term Sequelae | Long-term Sequelae |
|---|---|
|
|
Differential Diagnoses
Refsum Disease versus Adult Refsum-like Neuropathy (Peroxisomal Biogenesis Disorders)
Refsum Disease | Adult Refsum-like Neuropathy (Peroxisomal Biogenesis Disorders) |
|---|---|
Autosomal recessive inheritance due to mutations in the PHYH or PEX7 gene | Autosomal recessive inheritance with mutations in multiple PEX genes |
Isolated elevated plasma phytanic acid with normal very long chain fatty acids | Elevated very long chain fatty acids and phytanic acid with additional accumulation of other peroxisomal substrates |
Predominantly neurological symptoms with retinitis pigmentosa and ichthyosis | Progressive multisystem involvement including liver dysfunction and craniofacial abnormalities |
Refsum Disease versus Multiple Sclerosis
Refsum Disease | Multiple Sclerosis |
|---|---|
Usually presents in childhood to early adulthood but can vary | Typically young adults aged 20-40 years |
Chronic progressive course with accumulation of symptoms due to phytanic acid accumulation | Relapsing-remitting or progressive demyelinating episodes |
Normal brain MRI or nonspecific changes; diagnosis confirmed by elevated plasma phytanic acid | MRI showing multifocal white matter lesions with periventricular distribution |
Refsum Disease versus Vitamin E Deficiency Neuropathy
Refsum Disease | Vitamin E Deficiency Neuropathy |
|---|---|
Elevated plasma phytanic acid with normal vitamin E levels | Low serum vitamin E levels with normal phytanic acid |
Peripheral neuropathy with retinitis pigmentosa and ichthyosis | Symmetric peripheral neuropathy and ataxia without retinitis pigmentosa |
Requires dietary restriction of phytanic acid and plasmapheresis for symptom control | Improvement with vitamin E supplementation |
Refsum Disease versus Charcot-Marie-Tooth Disease (CMT)
Refsum Disease | Charcot-Marie-Tooth Disease (CMT) |
|---|---|
Autosomal recessive inheritance | Often autosomal dominant inheritance |
Elevated plasma phytanic acid levels | Normal plasma phytanic acid levels |
Neuropathy with systemic features including ichthyosis and retinitis pigmentosa | Slowly progressive distal muscle weakness and sensory loss without systemic features |
Refsum Disease versus Bassen-Kornzweig Syndrome (Abetalipoproteinemia)
Refsum Disease | Bassen-Kornzweig Syndrome (Abetalipoproteinemia) |
|---|---|
Normal lipid profile with elevated phytanic acid | Low serum cholesterol and triglycerides with acanthocytosis |
Neuropathy with ichthyosis and no fat malabsorption | Progressive ataxia and neuropathy with fat malabsorption and retinitis pigmentosa |
Genetic testing showing mutations in PHYH or PEX7 genes | Genetic testing showing mutations in MTTP or APOB genes |